Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Azad

Showing results (161-170 of 353) with videos related to

Pageof 36
Sort By:
Oncotarget|November 28, 2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancerJennifer L Bishop, Alexander Sio, Arkhjamil Angeles, et al.
Journal of Ophthalmology|May 16, 2020
Elevated Plasma Level of 8-Hydroxy-2'-deoxyguanosine Is Associated with Primary Open-Angle GlaucomaAltaf A Kondkar, Taif A Azad, Tahira Sultan, et al.
Future Oncology (London, England)|July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPCAndrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Seminars in Nuclear Medicine|July 3, 2023
Role of FDG PET/CT in Management of Patients with Prostate CancerDuncan E K Sutherland, Arun A Azad, Declan G Murphy, et al.
BMC Research Notes|July 25, 2019
Polymorphisms rs693421 and rs2499601 at locus 1q43 and their haplotypes are not associated with primary open-angle glaucoma: a case-control studyAltaf A Kondkar, Taif A Azad, Tahira Sultan, et al.
Archives of Virology|January 1, 1995
Expression and analysis of the NS2 protein of influenza A virusA C Ward, L A Castelli, A C Lucantoni, et al.
AIDS Research and Human Retroviruses|October 1, 1994
Fusogenic activity of amino-terminal region of HIV type 1 Nef proteinC C Curtain, F Separovic, D Rivett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate CancerKerry E Jewell, James P Buteau, Elizabeth Medhurst, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|June 26, 2018
Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirNiyaz A Azad, Zafar A Shah, Arshad A Pandith, et al.
European Urology Oncology|December 6, 2023
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?Niranjan J Sathianathen, Nathan Lawrentschuk, Badrinath Konety, et al.
Pageof 36

Showing results (161-170 of 353) with videos related to

Sort By:
Pageof 36
Oncotarget|November 28, 2014
PD-L1 is highly expressed in Enzalutamide resistant prostate cancerJennifer L Bishop, Alexander Sio, Arkhjamil Angeles, et al.
Journal of Ophthalmology|May 16, 2020
Elevated Plasma Level of 8-Hydroxy-2'-deoxyguanosine Is Associated with Primary Open-Angle GlaucomaAltaf A Kondkar, Taif A Azad, Tahira Sultan, et al.
Future Oncology (London, England)|July 14, 2025
Matching-adjusted indirect comparison of enzalutamide versus darolutamide doublet in mHSPCAndrew J Armstrong, Bhavik J Pandya, Hemant Singh Bhadauria, et al.
Seminars in Nuclear Medicine|July 3, 2023
Role of FDG PET/CT in Management of Patients with Prostate CancerDuncan E K Sutherland, Arun A Azad, Declan G Murphy, et al.
BMC Research Notes|July 25, 2019
Polymorphisms rs693421 and rs2499601 at locus 1q43 and their haplotypes are not associated with primary open-angle glaucoma: a case-control studyAltaf A Kondkar, Taif A Azad, Tahira Sultan, et al.
Archives of Virology|January 1, 1995
Expression and analysis of the NS2 protein of influenza A virusA C Ward, L A Castelli, A C Lucantoni, et al.
AIDS Research and Human Retroviruses|October 1, 1994
Fusogenic activity of amino-terminal region of HIV type 1 Nef proteinC C Curtain, F Separovic, D Rivett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 13, 2025
Safety and Efficacy of 20 Cycles of [<sup>177</sup>Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate CancerKerry E Jewell, James P Buteau, Elizabeth Medhurst, et al.
Asian Pacific Journal of Cancer Prevention : APJCP|June 26, 2018
Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of KashmirNiyaz A Azad, Zafar A Shah, Arshad A Pandith, et al.
European Urology Oncology|December 6, 2023
Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?Niranjan J Sathianathen, Nathan Lawrentschuk, Badrinath Konety, et al.
Pageof 36